Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1286840 | 0.83 | NOS1 (0.36) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL8785206 | 0.82 | ZDHHC7 (0.39) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL9352351 | 0.82 | KMT2A (0.33) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL6337940 | 0.80 | ALDH1A1 (0.42) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL217805 | 0.80 | ZDHHC7 (0.34) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL28198415 | 0.79 | LMNA (0.33) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL27905397 | 0.77 | ZDHHC7 (0.46) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL9079671 | 0.77 | ZDHHC7 (0.46) | NOS1NOS3NOS2KMT2AMEN1 | |
| SCHEMBL6932447 | 0.77 | KMT2A (0.36) | NOS1NOS3NOS2KMT2ALMNA | |
| SCHEMBL27747509 | 0.77 | NOS1 (0.36) | NOS1NOS3NOS2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12343323-B2 | Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof | SANTOLECAN PHARMACEUTICALS LLC (US) | 2025-07-01 | — | — | US | disclosed |
| CN-112351976-B | Taxane-lipid-polysaccharide double-type coupling body, preparation method and application thereof | 圣多利康制药责任有限公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3125949-B1 | DENDRONIZED METALLIC OXIDE NANOPARTICLES, A PROCESS FOR PREPARING THE SAME AND THEIR USES | CENTRE NAT RECH SCIENT (FR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4182305-A1 | NEMATICIDE COMPOUNDS, COMPOSITIONS, AND METHODS OF THEIR MAKING AND USE | Iowa State University Research Foundation, Inc. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20220370630-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER | SEIKAGAKU CORPORATION (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-4039279-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR MEDICINAL ACTIVE INGREDIENT TO SUBMUCOSA OF BLADDER | Seikagaku Corporation (JP) | 2022-08-10 | — | — | EP | disclosed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| CN-110642849-B | Protein degradation targeting chimera and preparation method and application thereof | 中南大学湘雅医院 | 2021-05-28 | — | — | CN | disclosed |
| EP-3812376-A1 | PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Santolecan Pharmaceuticals LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2021066175-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR MEDICINAL ACTIVE INGREDIENT TO SUBMUCOSA OF BLADDER | 生化学工業株式会社 | 2021-04-08 | — | — | WO | disclosed |
| WO-2004062625-A2 | MACROCYCLIC BETA-SECRETASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-6630469-B2 | Amino-pyrimidine and amino-triazine derivatives having 5-HT7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, cicadian rhythm disorders and hypertension | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-07 | — | — | US | disclosed |
| EP-1280781-A4 | 5-HT 7 RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2003-08-06 | — | — | EP | disclosed |
| EP-1280781-A1 | 5-HT 7 RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| US-20020032199-A1 | 5-HT7 receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-14 | — | — | US | disclosed |
| WO-2001085701-A1 | 5-HT7 RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
| US-5998415-A | Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors | MERCK SHARP & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| WO-1997016446-A1 | BICYCLIC HETEROARYL-ALKYLENE-(HOMO)PIPERAZINONES AND THIONE ANALOGUES THEREOF, THEIR PREPARATION AND THEIR USE AS SELECTIVE AGONISTS OF 5-HT1-LIKE RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343323-B2 | Taxane-lipid-polysaccharide dual conjugates, preparation methods thereof and uses thereof | DDOST, UGT2B17, UGT1A7 | NOS1 4486/4885NOS3 4441/4885NOS2 4214/4885 |
| US-20020032199-A1 | 5-HT7 receptor antagonists | HTR7, HTR5A, HTR1A | NOS1 2888/4885NOS3 2916/4885NOS2 3085/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | NOS1 4486/4885NOS3 4441/4885NOS2 4214/4885 |
| US-20220370630-A1 | TRANSMUCOSAL DELIVERY SYSTEM FOR PHARMACEUTICAL ACTIVE INGREDIENT TO SUBMUCOSAL TISSUE OF BLADDER | PIGS, MMP7, CD44 | NOS1 3207/4885NOS3 2855/4885NOS2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.